Celldex selloff creates buying opportunity, says Guggenheim
The Fly

Celldex selloff creates buying opportunity, says Guggenheim

Guggenheim analyst Yatin Suneja notes that Celldex (CLDX) presented full data from the Phase 2 trial of barzolvolimab in two common forms of chronic inducible urticaria, or CIndU, as a late breaking oral presentation at ACAAI 2024 last Saturday and believes the recent selloff in the shares over the past month is “unwarranted” as the firm argues “data continue to look good.” Guggenheim reiterates a Buy and $90 price target on Celldex shares.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App